Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Nebivolol Hypertension Drug Patent Protection Expected Through 2015

Executive Summary

Mylan expects to secure patent protection for the hypertension drug nebivolol until 2015, six years after the composition of matter patent expires, President and Chief Operating Officer Richard Moldin told analysts.
Advertisement

Related Content

Mylan Places Big Bet On Antihypertensives: $4 Bil. Deal For King
Mylan Places Big Bet On Antihypertensives: $4 Bil. Deal For King
Roche Accutane Prescriber Registry Added To Pregnancy Prevention Program
Roche Accutane Prescriber Registry Added To Pregnancy Prevention Program
Accutane Psychiatric Safety Trial Planned: Roche Prepares For Hearings
Accutane Psychiatric Safety Trial Planned: Roche Prepares For Hearings
Dr. Reddy's Looks To Acquire U.S. Generics Company Following $115 Mil. IPO
Par 7.5 Mg Buspirone Aims To Capture Portion of 15 Mg Split-Tablet Market
Bristol Glucophage XR Gets 35% Of New Rxs From Metformin Switches
Bristol Glucophage XR Gets 35% Of New Rxs From Metformin Switches
Advertisement
UsernamePublicRestriction

Register

PS037666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel